Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01234779 · ClinicalTrials.gov registry record · Phase 2
A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 301
- Enrollment target
NCT01234779 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 301 participants.
The verdict
NCT01234779, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 301 participants
- Enrollment target
Study Summary
This randomized, double-blind, placebo- and active-controlled, parallel group study will evaluate the safety and efficacy of RO4917838 (bitopertin) in patients with acute exacerbation of schizophrenia. Patients will be randomized to receive either RO4917838 10 mg or RO4917838 30 mg or olanzapine 15 mg or placebo orally daily for 4 weeks as inpatients, with a 4-week follow-up period.
Interventions
- DRUG placebo
- DRUG olanzapine
- DRUG bitopertin [RO4917838]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 301 participants |
| Start Date | 2011-02 |
| Est. Completion | 2012-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01234779
The ClinicalTrials.gov registry entry for NCT01234779 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 301 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT01234779 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01234779 about?
NCT01234779 is a clinical study titled "A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia". This randomized, double-blind, placebo- and active-controlled, parallel group study will evaluate the safety and efficacy of RO4917838 (bitopertin) in patients with acute exacerbation of schizophrenia. Patients will be randomized to receive either RO4917838 10 mg or RO4917838 30 mg or olanzapine 15 ...
What is the current status of trial NCT01234779?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 301 participants. The study started on 2011-02. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01234779?
The interventions under investigation include: placebo (DRUG), olanzapine (DRUG), bitopertin [RO4917838] (DRUG).
Who is sponsoring clinical trial NCT01234779?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.